阿加曲班治疗急性进展性脑梗死的疗效观察

Curative Effect Observation of the Progress Acute Cerebral Infarction Treated by Argatroban

目的探讨阿加曲班治疗急性脑梗死的临床疗效及其可能的作用机制。方法 56例急性进展性脑梗死患者随机分为阿加曲班治疗组(治疗组,26例)和常规治疗组(对照组,30例)。治疗组给予静脉滴注阿加曲班,开始2d内,60mg/d,持续静脉滴注,其后的5d内,20mg/d,早晚各1次,7d后给予拜阿司匹林,奥扎格雷钠,依达拉奉等治疗。对照组不用阿加曲班,其他同治疗组。两组患者在治疗前与治疗后14d进行NIHSS评分,并监测凝血功能等指标变化及治疗期间不良反应。结果治疗后14d两组患者神经功能缺损评分较治疗前均有改善(均P<0.01),治疗组神经功能缺损评分明显低于对照组(P<0.01);治疗组患者神经功能缺损评分减少值明显高于对照组(P<0.05)。两组均无明显不良反应。结论急性进展性脑梗死应用阿加曲班治疗安全、有效。

Objective Discuss, Argatroban in treatment of acute cerebral infarction clinical curative effect and its possible mechanism. Methods 56 patients with acute progressive cerebral infarction were randomly divided into treatment group, argatroban （the treatment group, 26cases） and routine treatment group （control group, 30cases）. Treatment group was given intravenous drip, Argatroban, began to 2 days, 60 mg daily, continuous intravenous drip, the following 5 days, 20 mg daily, morning and evening each once, after 7 days give aspirin, Ozagrel sodium, in accordance with edaravone in treatment, etc. Control group don＇t have to, argatroban, other are the same as the treatment group. NIHSS score of two groups of treatment for 14 days, and watch the blood coagulation function index changes and adverse reactions during the observation period treatment. Results 14 d after treatment of neural function defect score than before treatment in both groups were improved（P〈0.01）.The treatment group neural function defect score signiifcantly lower than the control group（P〈0.01）. Treatment group patients with nerve function defect score reduction value is signiifcantly higher than the control group（P〈0.05）. In the two groups had no obvious adverse reactions.Conclusion Application in argatroban of acute progressive cerebral infarction treatment is safe, effective.